Vaccine Adjuvant Platform

Stimulator of Interferon Genes (STING) regulates the activity of tissue resident myeloid Antigen Presenting Cells (APCs), the primary target of a prophylactic influenza vaccine adjuvant. The team at Silicon Therapeutics is developing a proprietary small molecule STING agonist formulated in combination with influenza antigens to provide optimal APC activation and increased antigen cross-presentation, resulting in a more rapid and effective development of a Th1 T cell response, concomitant B cell activation and IgG2a/b/c class switching.

The combined effect will lead to higher neutralizing antibody titers, development of long-lived memory lymphocyte populations, a more diverse antibody/TCR repertoire and ultimately better protection against viral challenge. We predict the therapeutic effect will improve the current influenza vaccine protection rates (~50%) and elicit protection against non-targeted influenza HA subtypes.